The purpose of this one year administrative supplement program is to provide deep quality control and molecular phenotyping of ADRD iPSC lines. This program will fund whole genome sequencing (WGS) to fully characterize the genomic integrity of iPSC lines and compare against matched donor DNA WGS (ongoing through other support) for detecting mutation rates between the sources of DNA, source cell material (PBMC & fibroblasts). RNA-Seq and DNA methylation array analysis for the iPSC lines will provide gene expression profiles and methylation signatures to the respective parental cell type to assess the extent somatic memory exists and if this varies across different reprograming protocols. Additionally, we would utilize these data to determine whether somatic mutations occurring during reprogramming have functional consequences in gene expression patterns. This supplement will extend the scientific goals of the NINDS Human Cell and Data Repository (NHCDR) by providing insights into how genetic variants influence convergent ADRD disease pathways.
This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.
The purpose of this Notice is to inform potential applicants of the NIHs interest in supporting research on interventions designed to change the culture to mitigate or eliminate sexual harassment in the biomedical research enterprise. This notice aligns with the Anti-Sexual Harassment policy notice released by NIH as well as recommendations made in the December 2019 Report from the Working Group to the Advisory Committee to the NIH Director on Changing the Culture to End Sexual Harassment.
SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031) with an emphasis on providing students with research opportunities and enriching the research environments at the applicant institutions. The purpose of SuRE-First awards is to support research grants for faculty investigators at eligible institutions who have not had prior independent external research grants.
SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research NOT-OD-20-031 with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions. ?The purpose of SuRE awards is to provide research grant support for faculty investigators at eligible institutions who haveprior experience in leading externally-funded, independent research butare not currently funded by any NIH Research Project Grants with the exception of SuRE or SuRE-First awards.
Between 40 and 70% of older adults suffer from sleep disturbances or disorders, which are especially prevalent among patients with Alzheimer's Disease and Alzheimers Disease Related Dementias (AD/ADRD), i.e., frontotemporal dementia, Lewy body dementia, vascular contributions to cognitive impairment and dementia, and multiple etiology dementias. The AD Research Summits specifically recommends to invest in understanding the integrative physiology of sleep and elucidating the short- and long-term consequences of disrupted and optimized sleep on brain aging and AD. Moreover, NIAs AD/ADRD Research Implementation Milestone 2.F plans to "create new research programs aimed at understanding the integrative physiology of circadian rhythms and sleep and its impact on brain aging and the risk of AD and AD-related dementias at multiple levels (epigenetic, gene expression, proteomic, neuronal, network, systems) to identify new targets and approaches for AD prevention." The purpose of this one-year administrative supplement program is to facilitate collaborative research to better understand the bi-directional relationship between chronic sleep disturbances/circadian disruption and AD/ADRD pathogenesis. This notice encourages eligible NINDS awardees in the AD/ADRD research community to apply for supplemental funds to establish new collaborations with sleep/circadian researchers for the advancement of research on the association between sleep disturbances/circadian disruption with ADRD. This initiative aims to investigate the potential of sleep/circadian-related treatment as a modifier of the development and progression of neurodegeneration. The proposed studies must be within the scope of the peer-reviewed activities specified within the NINDS parent award, and collaborators may not have a prior history of collaboration. Active awards with project end dates in FY 2022 or later are eligible. The award may not be entering or in a terminal no-cost extension in FY 2021.
This NINDS Notice of Special Interest (NOSI) announces the availability of administrative supplements to support hyperacute magnetic resonance imaging (MRI) of the brain in stroke patients to understand how lesion evolution and hyperacute brain changes affect cognitive trajectories and outcomes.
NINDS is interested in supplementing applications to conduct research on the effects of COVID-19 on the development of, or disease progression in, AD/ADRD. For example, anosmia is a risk factor for developing LBD and AD dementiaand anosmia is a common sequelae of COVID-19 infection, but it is unclear whether COVID-19 infected individuals with anosmia are also at greater risk for developing cognitive impairment and dementia. Similarly, although subjects with AD/ADRD are likely to worsen cognitively during COVID-19 infection, research is lacking as to whether they return to baseline after recovery from infection or whether there is accelerated progression of cognitive decline. Applicants requesting supplements to active NINDS-funded human subjects projects that will address these research questions, for example bytesting for COVID-19, anosmia, cognitive assessments, and biomarker assessments (neuroimaging, fluid-based), are encouraged under this opportunity.
This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.